Abstract
Heparin-coated circuits have been repeatedly proven to reduce the inflammatory response and foreign surface activation triggered upon initiation of cardiopulmonary bypass (CPB). In recent years, increasing numbers of studies are proving significant reductions in postoperative blood loss and transfusion requirements and improvements in clinical outcomes as a result of heparin-coated circuits. These results are promising steps in our efforts to improve CPB, as our patient population gets older and more complicated.
MeSH terms
-
Anticoagulants / administration & dosage*
-
Anticoagulants / pharmacology
-
Blood Coagulation / drug effects
-
Blood Coagulation Factors / drug effects
-
Cardiopulmonary Bypass / adverse effects
-
Cardiopulmonary Bypass / instrumentation*
-
Cardiopulmonary Bypass / methods
-
Coated Materials, Biocompatible
-
Drug Delivery Systems*
-
Heparin / administration & dosage*
-
Heparin / pharmacology
-
Humans
-
Inflammation / prevention & control*
-
Postoperative Hemorrhage / prevention & control
-
Risk Factors
Substances
-
Anticoagulants
-
Blood Coagulation Factors
-
Coated Materials, Biocompatible
-
Heparin